Sponsored Clinical Trials
1. Daiichi Sankyo - ENGAGE-AF A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of DU-176b Versus Warfarin In Subjects with Atrial Fibrillation – Effective aNticoaGulation with Factor xA Next GEneration in Atrial Fibrillation (ENGAGE AF – TIMI 48) 2. TRILOGY-ACS Study The TRILOGY-ACS Study is a global Phase III, double-blind, double-dummy, parallel-group, randomized-controlled trial. TRILOGY-ACS is designed to test the hypothesis that the combination of aspirin and prasugrel, a novel thienopyridine inhibiting the P2Y12 platelet receptor, is superior to aspirin and clopidogrel in the treatment of medically managed patients enrolled within 10 days of the unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI) index event. The total study population of ~10,300 patients will be enrolled at 800 sites globally, with an estimated 7800 patients <75 years of age and 2500 patients ≥75 years of age. TRILOGY-ACS is the first study to investigate the clinical efficacy of prasugrel in medically managed patients with UA/NSTEMI. For more details contact our Research Team |